The debt reduction is a credit-positive signal that strengthens the balance sheet and reduces future dilution risk. Monitor for further repurchases or any update on cash runway, as the ~$29M cash outlay may impact near-term liquidity for a clinical-stage biotech.
OMER drugs
OMER drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $9.53entry
- T+1 · 4mo ago +3.25%α +3.37% · $9.84
- T+5 · 4mo ago +18.99%α +20.22% · $11.34
- T+20 · 3mo ago +80.38%α +77.82% · $17.19
- T+60 · 5w ago +98.11%α +94.14% · $18.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omeros repurchased and retired $30.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 in two tranches, including a $14.5 million repurchase completed on July 20, 2026 for ~$29.0 million (including accrued interest). Approximately $40.3 million in notes remain outstanding. The debt reduction lowers leverage, future interest expense, and potential equity dilution from conversion.
Key Facts
- Repurchased $14.5M principal of 9.50% Convertible Senior Notes due 2029 for ~$29.0M on July 20, 2026
- Combined with prior $16.0M repurchase, total retired is $30.5M aggregate principal
- Remaining outstanding notes: ~$40.3M principal
- Repurchases were privately negotiated with note holders
Financial Impact
Retired 43% of outstanding convertible notes ($30.5M of ~$70.8M originally outstanding), reducing annual interest expense by ~$2.9M and eliminating potential dilution from conversion of those notes
Risk Factors
- Cash used for repurchase (~$29M) could reduce funding available for R&D and operations
- Remaining $40.3M in convertible notes still represent potential dilution if converted
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-023886 |
| Document: 0001437749-26-023886-index-headers.html | 0001437749-26-023886 |
| Document: 0001437749-26-023886-index.html | 0001437749-26-023886 |
| Document: 0001437749-26-023886.txt | 0001437749-26-023886 |
Track record
12 reports on OMER
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
- Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
- Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
- Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
- Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
- Jul 20, 202617w ago 8-K Bullish 5/10 Viewing Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
- Jul 6, 202619w ago 8-K Neutral 4/10 Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
- Jun 18, 202621w ago 8-K Bullish 5/10 Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers